Cargando…

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells

CD38 is a target for immunotherapy of multiple myeloma. Llama-derived CD38-specific nanobodies allow easy reformatting into mono-, bi- and multispecific proteins. To evaluate the utility of nanobodies for constructing CD38-specific nanobody-based killer cell engagers (nano-BiKEs), we generated half-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hambach, Julia, Fumey, William, Stähler, Tobias, Gebhardt, Anna Josephine, Adam, Gerhard, Weisel, Katja, Koch-Nolte, Friedrich, Bannas, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150782/ https://www.ncbi.nlm.nih.gov/pubmed/35651607 http://dx.doi.org/10.3389/fimmu.2022.838406

Ejemplares similares

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
por: Pape, Luca Julius, et al.
Publicado: (2022)

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022)

Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
por: Bannas, Peter, et al.
Publicado: (2017)

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
por: Schriewer, Levin, et al.
Publicado: (2020)

Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD(+) Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells
por: Baum, Natalie, et al.
Publicado: (2020)

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
por: Schütze, Kerstin, et al.
Publicado: (2018)

Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
por: Hambach, Julia, et al.
Publicado: (2020)

Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
por: Bannas, Peter, et al.
Publicado: (2018)

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo
por: Fumey, William, et al.
Publicado: (2017)

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
por: Bannas, Peter, et al.
Publicado: (2015)

Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells
por: Baum, Natalie, et al.
Publicado: (2021)

Immuno-targeting the multifunctional CD38 using nanobody
por: Li, Ting, et al.
Publicado: (2016)

Nanobodies: new avenue to treat kidney disease
por: Wanner, Nicola, et al.
Publicado: (2021)

Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity
por: Menzel, Stephan, et al.
Publicado: (2018)

Nanobodies as modulators of inflammation: potential applications for acute brain injury
por: Rissiek, Björn, et al.
Publicado: (2014)

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
por: Tang, Yuanyan, et al.
Publicado: (2022)

Current Approaches and Future Perspectives for Nanobodies in Stroke Diagnostic and Therapy
por: Jank, Larissa, et al.
Publicado: (2019)

Fully synthetic platform to rapidly generate tetravalent bispecific nanobody–based immunoglobulins
por: Misson Mindrebo, Laetitia, et al.
Publicado: (2023)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
por: Mei, Heng, et al.
Publicado: (2021)

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
por: Fayon, Maxime, et al.
Publicado: (2021)

Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors
por: Eichhoff, Anna Marei, et al.
Publicado: (2019)

Bispecific costimulatory molecules for activation of tumor-killing lymphocytes
por: Weth, R, et al.
Publicado: (2004)

Effective targeting of microglial P2X7 following intracerebroventricular delivery of nanobodies and nanobody-encoding AAVs
por: Pinto-Espinoza, Carolina, et al.
Publicado: (2022)

P815: HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT MULTIPLE MYELOMA CELL KILLING
por: Hart, Kevin C., et al.
Publicado: (2023)

Design of nanobody-based bispecific constructs by in silico affinity maturation and umbrella sampling simulations
por: Bai, Zixuan, et al.
Publicado: (2022)

Nanobody‐mediated complement activation to kill HIV‐infected cells
por: Pedersen, Maria Lange, et al.
Publicado: (2023)

A simple, sensitive, and low‐cost FACS assay for detecting antibodies against the native SARS‐CoV‐2 spike protein
por: Hambach, Julia, et al.
Publicado: (2021)

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies
por: Zitron, Ian M, et al.
Publicado: (2013)

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
por: Weisel, Katja
Publicado: (2016)

A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation
por: Eden, Thomas, et al.
Publicado: (2018)

Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
por: Hao, Shuai, et al.
Publicado: (2022)

Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
por: Xia, Baijin, et al.
Publicado: (2023)

P859: ANTI-CD38 NANOBODY JK36 ALLOWS RELIABLE MRD DETECTION IN DARATUMUMAB TREATED MULTIPLE MYELOMA PATIENTS
por: Meseguer Martinez, E., et al.
Publicado: (2022)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
por: Castaneda-Puglianini, Omar, et al.
Publicado: (2021)

A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
por: Hanke, Leo, et al.
Publicado: (2022)

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells
por: Liu, Yanlong, et al.
Publicado: (2022)

Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma
por: Ma, Linlin, et al.
Publicado: (2022)

Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy
por: Yang, Xiao-mei, et al.
Publicado: (2023)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_amv2nf9eetg58kq3npaamcpkga